MedTrace Logo

Multihance Versus Magnevist in Breast MRI

NCT00486473 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2010-07-15

No results posted yet for this study

Summary

To show if one MRI contrast agent is better than another one in the diagnosis of malignant breast lesions compared to histopathology

Conditions

Interventions

DRUG

Multihance

0.5 Molar at a single dose injection

DRUG

Magnevist

0.5M at a single dose injection

Sponsors & Collaborators

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Principal Investigators

  • Gianpaolo Pirovano, MD · Bracco Dianostics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00486473 on ClinicalTrials.gov